Skip to main content
NIH Intramural Research Program, Our Research Changes Lives

Navigation controls

  • Search
  • Menu

Social follow links

  • Podcast
  • Instagram
  • Twitter
  • YouTube
  • LinkedIn

Main navigation

  • About Us
    • What Is the IRP?
    • History
    • Honors
      • Nobel Prize
      • Lasker Award
      • Breakthrough Prize
      • Shaw Prize
      • Presidential Early Career Award for Scientists and Engineers (PECASE)
      • Presidential Medal of Freedom
      • National Medal of Science
      • Searle Scholars
      • The National Academy of Sciences
      • The National Academy of Medicine
      • The National Academy of Engineering
      • The American Academy of Arts and Sciences
      • National Medal of Technology & Innovation
      • Samuel J. Heyman Service to America Medals
      • Crafoord Prize
      • Fellows of the Royal Society
      • Canada Gairdner Awards
    • Organization & Leadership
    • Our Programs
      • NCI
      • NEI
      • NHGRI
      • NHLBI
      • NIA
      • NIAAA
      • NIAID
      • NIAMS
      • NIBIB
      • NICHD
      • NIDA
      • NIDCD
      • NIDCR
      • NIDDK
      • NIEHS
      • NIMH
      • NIMHD
      • NINDS
      • NINR
      • NLM
      • CC
      • NCATS
      • NCCIH
    • Research Campus Locations
    • Contact Information
  • Our Research
    • Scientific Focus Areas
      • Biomedical Engineering & Biophysics
      • Cancer Biology
      • Cell Biology
      • Chemical Biology
      • Chromosome Biology
      • Clinical Research
      • Computational Biology
      • Developmental Biology
      • Epidemiology
      • Genetics & Genomics
      • Health Disparities
      • Immunology
      • Microbiology & Infectious Diseases
      • Molecular Biology & Biochemistry
      • Molecular Pharmacology
      • Neuroscience
      • RNA Biology
      • Social & Behavioral Sciences
      • Stem Cell Biology
      • Structural Biology
      • Systems Biology
      • Virology
    • Principal Investigators
      • View by Investigator Name
      • View by Scientific Focus Area
    • Accomplishments
      • View All Accomplishments by Date
      • View All Health Topics
      • The Body
      • Health & Wellness
      • Conditions & Diseases
      • Procedures
    • Accelerating Science
      • Investing in Cutting-Edge Animal Models
      • Creating Cell-Based Therapies
      • Advancing Computational and Structural Biology
      • Combating Drug Resistance
      • Developing Novel Imaging Techniques
      • Charting the Pathways of Inflammation
      • Zooming in on the Microbiome
      • Uncovering New Opportunities for Natural Products
      • Stimulating Neuroscience Research
      • Pursuing Precision Medicine
      • Unlocking the Potential of RNA Biology and Therapeutics
      • Producing Novel Vaccines
    • Research in Action
      • View All Stories
      • Battling Blood-Sucking Bugs
      • Unexpected Leads to Curb Addiction
      • Shaping Therapies for Sickle Cell Disease
      • The Mind’s Map Maker
    • Trans-IRP Research Resources
      • Supercomputing
    • IRP Review Process
    • Commercializing Inventions
  • NIH Clinical Center
    • Clinical Center Facilities
    • Clinical Faculty
    • Advancing Translational Science
    • Clinical Trials
      • Get Involved with Clinical Research
      • Physician Resources
  • News & Events
    • In the News
    • I am Intramural Blog
    • Speaking of Science Podcast
    • SciBites Video Shorts
    • The NIH Catalyst Newsletter
    • Events
  • Careers
    • Faculty-Level Scientific Careers
    • Trans-NIH Scientific Recruitments
      • Stadtman Tenure-Track Investigators
        • Science, the Stadtman Way
      • Lasker Clinical Research Scholars
      • Independent Research Scholar
    • Scientific & Clinical Careers
    • Administrative Careers
  • Research Training
    • Program Information
    • Training Opportunities
    • NIH Work/Life Resources
The NIH Catalyst: A Publication About NIH Intramural Research

National Institutes of Health • Office of the Director | Volume 25 Issue 6 • November–December 2017

Newest Lasker Clinical Research Scholar: Anish Thomas, M.D.

BY LAURA STEPHENSON CARTER

Meet the newest NIH Lasker Clinical Research Scholar: Anish Thomas whose clinical research focuses on small-cell lung cancer (SCLC), one of the most aggressive human cancers.

The Lasker Clinical Research Scholars Program, an “intramural–extramural” NIH program in partnership with the Albert and Mary Lasker Foundation, aims to grow the diminishing pool of talented physician-scientists by providing the necessary financial support to establish their careers. Lasker Scholars receive a unique combination of NIH funding for clinical research for up to 10 years. In the first phase of the program, Scholars receive appointments for five to seven years as tenure-track investigators within the NIH Intramural Research Program with independent budgets. In the second phase, successful Scholars will receive up to three years of NIH support for their research at an extramural research facility; or the Scholar can be considered to remain as an investigator within the intramural program. To learn more, go to https://www.nih.gov/research-training/lasker-clinical-research-scholars.

The following is a lightly edited version of the interview with Anish Thomas who joins 14 others in the NIH Lasker Clinical Research Scholar program.

ANISH THOMAS, M.B.B.S., M.D.

Lasker Clinical Research Scholar, Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute

Anish Thomas

PHOTO CREDIT: CHIA-CHI CHARLIE CHANG

The newest Lasker Clinical Research Scholar, Anish Thomas, conducts clinical research on small-cell lung cancer, the most lethal form of lung cancer.

EDUCATION: St. John’s Medical College, Bangalore, India (M.B.B.S. and M.D.)

TRAINING: Postgraduate training, St. John’s Medical College; internal medicine residency, State University of New York Upstate Medical University (Syracuse, N.Y.); training in medical oncology at NCI and in hematology at NHLBI

CAME TO NIH: In 2013 as a fellow for training; was a staff clinician in NCI’s Thoracic and GI Oncology Branch (2013–2016); in 2016 became a staff clinician in the NCI’s Developmental Therapeutics Branch; became a Lasker Scholar in September 2017

WEBSITE: https://www.irp.nih.gov/pi/anish-thomas

Research Focus: I am a clinical researcher with a focus on small-cell lung cancer (SCLC), one of the most aggressive human cancers. The goal of my research is to systematically develop more-effective therapies for patients with SCLC and similar chemotherapy-refractory tumors by targeting key pathways involved in DNA replication, repair, and chromatin remodeling. I design and conduct phase 1 and phase 2 clinical trials that examine strategies to determine how enhancing DNA replicative stress can best be used in the clinic in combination with existing therapies to improve patient outcomes. This work stems from my intramural and extramural collaborations with basic scientists, translational researchers, surgical pathologists, and clinicians, all of whom are interested in various facets of SCLC—from understanding the biology of genomic instability, chromatin regulation, and immunomodulation in solid tumors to identifying cancer dependencies that drive responses.

How did you become interested in science and your field? I completed medical school and then went through general-medicine training (similar to a residency in the United States) in India and worked there for some time before coming to the United States. During my training in India, we would see on an average of 50 to 60 patients a day, most with infectious diseases. I was fortunate to work with Dr. Cecil Ross, one of the few people in India at the time who treated hematological cancers and bone-marrow-failure syndromes. I decided to look for additional training opportunities in the United States mainly to build on my clinical expertise and was hoping to get more involved in research.

For about a year after coming to the United States and during my residency at SUNY Upstate Medical University, I worked in the lab of former NCI researcher Bernard Poiesz. (In 1980, the year before the first cases of AIDS were reported, Poiesz, Frank Ruscetti, and colleagues at NCI discovered and characterized the first human cancer-causing retrovirus—human T-cell lymphotropic virus–type 1, HTLV-1—in a patient with leukemia/lymphoma, and they later identified HTLV-2.) []

It was my first time working in a lab, and the experience gave me an opportunity to learn its language. Although I was more fluent in the language of patient care, this experience allowed me to move and communicate easily in both worlds.

My decision to go into thoracic oncology was influenced by the exceedingly high human cost of SCLC (more people die from lung cancer each year than from colon, breast, and prostate cancers combined) and by my work with Giuseppe Giaccone, then chief of NCI’s Medical Oncology Branch. Once I decided to go into thoracic oncology, the decision to consider SCLCs was obvious. SCLC is the most lethal form of lung cancer, and other than few modifications here and there, there have been no major changes in the treatment of this cancer. What was considered state-of-the-art in the early 1980s is still state-of-the-art today. I may be naive, but I am hoping our work can make a difference.

What discoveries have you made? I have been involved in the design and conduct of some practice-changing clinical trials. One was a study of sunitinib in people with thymic cancers, which are generally fatal orphan cancers with no standard treatment options after chemotherapy fails. In our trial, sunitinib showed unprecedented responses in thymic-carcinoma patients. Based on these results, the National Comprehensive Cancer Network guidelines now recommend sunitinib for recurrent thymic carcinoma.

I was also involved with one of the first reported , the Molecular Profiling and Targeted Therapies in Advanced Thoracic Malignancies (. (Traditional clinical trials focus on a particular cancer type, but basket trials concentrate on a specific mutation.) [] We enrolled over 600 patients with chemotherapy-refractory advanced non-small-cell lung cancer, small-cell lung cancer, and thymic malignancies. Patients underwent molecular profiling of fresh or archival biopsies and were grouped by both molecular alterations and tumor histology to receive several targeted therapies. Basket trials are now used extensively in evaluating the so-called personalized-medicine hypothesis in multiple settings.

What are the advantages to working in the NIH IRP? On the patient-care front, the NIH Clinical Center offers fantastic infrastructure and facilities and an atmosphere that allows you to focus on patients without having to worry about where they are from or how they are going to pay for a test or intervention. On the research front, the NIH IRP has many experts who are potential collaborators.

What is most exciting about your work? Being able to work at the intersection of the human side of medicine and cutting-edge science. Each day is an opportunity to go back and forth between the two. It is a privilege and an inspiration to meet people—and their families—from all walks of life who are facing life-changing decisions. (Of course, you wonder what decisions you’d make under similar circumstances.) It is also enriching to be able to work closely with staff who try their best to make a positive difference. It is also great to work with scientists and clinicians who have made fundamental discoveries that have influenced the way we understand and treat cancers.

What do you like to do outside of work? I enjoy spending time with my wife and four young children.

If I had more time I would…spend more time with my family, maybe read a book, and sleep.

Would you like to tell us anything else? I am a clinician at heart and now am trying to rediscover the power of clinical observation. It was emphasized a lot during my training in India: We’d have to identify the 20-plus signs of aortic regurgitation and would have to diagnose the four different valve pathologies in a patient with rheumatic heart disease. With a combination of good clinical observation and some phenotype-to-genotype studies, I hope we can identify subsets of diseases that may be therapeutically relevant.

This page was last updated on Friday, April 8, 2022

  • Issue Overview
  • Features
    • 2017 Research Festival: The Brain, Inflammation, Cancer, and More
    • 2017 Research Festival: Plenary Sessions
    • 2017 Research Festival: Selected Concurrent Symposia
    • Gisela Storz, Ph.D.: Discovering Big Secrets in Small Genes
    • Newest Lasker Clinical Research Scholar: Anish Thomas, M.D.
    • Robotic Exoskeleton Helps Alleviate Crouch Gait in Children with Cerebral Palsy
    • Insights from Former Surgeon General Vivek Murthy
    • History of the National Library of Medicine
  • Departments
    • From the Deputy Director for Intramural Research
    • News Briefs
    • Colleagues: Recently Tenured
    • Research Briefs
    • The SIG Beat: New SIGs
    • Photographic Moment
    • Announcements: Kudos
    • Announcements
  • Issue Contents
  • Download this issue as a PDF

Catalyst menu

  • Current Issue
  • Previous Issues
  • About The NIH Catalyst
  • Contact The NIH Catalyst
  • Share Your Story
  • NIH Abbreviations

Subscribe Today!

Subscribe to The NIH Catalyst Newsletter and receive email updates.

Subscribe

Get IRP Updates

Subscribe

  • Email
  • Print
  • Share Twitter Facebook LinkedIn

Main navigation

  • About Us
    • What Is the IRP?
    • History
    • Honors
    • Organization & Leadership
    • Our Programs
    • Research Campus Locations
    • Contact Information
  • Our Research
    • Scientific Focus Areas
    • Principal Investigators
    • Accomplishments
    • Accelerating Science
    • Research in Action
    • Trans-IRP Research Resources
    • IRP Review Process
    • Commercializing Inventions
  • NIH Clinical Center
    • Clinical Center Facilities
    • Clinical Faculty
    • Advancing Translational Science
    • Clinical Trials
  • News & Events
    • In the News
    • I am Intramural Blog
    • Speaking of Science Podcast
    • SciBites Video Shorts
    • The NIH Catalyst Newsletter
    • Events
  • Careers
    • Faculty-Level Scientific Careers
    • Trans-NIH Scientific Recruitments
    • Scientific & Clinical Careers
    • Administrative Careers
  • Research Training
    • Program Information
    • Training Opportunities
    • NIH Work/Life Resources
  • Department of Health and Human Services
  • National Institutes of Health
  • USA.gov

Footer

  • Home
  • Contact Us
  • IRP Brand Materials
  • HHS Vulnerability Disclosure
  • Web Policies & Notices
  • Site Map
  • Search